Done: Who It's Best For (Ideal Patient Profile, Cost, and Clinical Fit)

What Done Actually Is

Done operates as a subscription telehealth service connecting patients with nurse practitioners and physicians who diagnose and treat ADHD via video appointments. The platform uses a screening questionnaire based on the Adult ADHD Self-Report Scale (ASRS-v1.1), a validated 6-item tool developed by the World Health Organization [1]. After screening, patients schedule a synchronous video evaluation with a prescriber.

The service launched in 2020 during the COVID-19 public health emergency, which temporarily relaxed DEA requirements for prescribing controlled substances via telehealth. Since the permanent reinstatement of in-person requirements under the DEA's 2025 telemedicine rule, Done has adapted its protocols to comply with audio-video evaluation standards for Schedule II prescriptions [2].

Done is not a diagnostic testing center. It does not offer neuropsychological evaluation, continuous performance testing (CPT), or psychotherapy. Patients who need those services require referral elsewhere.

The Ideal Patient Profile for Done

The adult most likely to benefit from Done fits a specific clinical and logistical profile. This person is between 25 and 45, employed, and has long suspected they have ADHD but never received a formal evaluation. They live in a region with a 3- to 6-month wait for outpatient psychiatry. A 2022 JAMA Network Open study found that the median wait time for a new outpatient psychiatry appointment in the United States was 67 days, with some markets exceeding 6 months [3].

The ideal Done patient also meets these criteria:

• No active substance use disorder. The American Academy of Addiction Psychiatry recommends against prescribing stimulants to patients with untreated or active substance use disorders [4]. Done's intake screens for this, though the depth of screening varies by provider.
• No complex comorbidity requiring integrated care. Patients with bipolar disorder, active psychosis, or severe anxiety may need stabilization before stimulant initiation. The American Psychiatric Association's 2019 practice guidelines emphasize that ADHD medications should be prescribed only after mood destabilization risks are assessed [5].
• Comfort with a subscription model. Done charges monthly regardless of whether the patient needs a medication adjustment. Patients who prefer fee-for-service or insurance-based care are not well served.
• Prior positive response to stimulant medication (for returning patients). Adults who previously took methylphenidate or amphetamine salts and lost access due to a provider move or insurance change find Done's quick onboarding useful.

The patient who does not fit: someone with untreated bipolar II, active alcohol dependence, a history of stimulant misuse, or a need for combined psychotherapy and pharmacotherapy.

Is Done Legitimate?

Done is a registered medical practice operating under state medical board oversight. Its providers hold active DEA registrations and state licenses. The platform is not a pharmacy; prescriptions are sent to the patient's pharmacy of choice.

Done and Cerebral have faced public questions about telehealth stimulant prescribing, but public information does not establish specific corporate findings or resulting internal policy changes at Done.

The broader clinical question is whether Done's evaluation depth supports a careful ADHD diagnosis. A comprehensive evaluation generally considers symptoms, impairment, history, comorbidities, and alternative explanations; visit length alone does not establish adequacy.

A 2023 JAMA Internal Medicine study analyzing telehealth ADHD prescribing patterns found that patients receiving stimulant prescriptions via telehealth platforms were less likely to receive follow-up behavioral interventions compared to those seen in traditional settings (18.2% vs. 34.7%, P<0.001) [8]. This gap matters clinically because the NIMH Multimodal Treatment Study of ADHD (MTA, N=579) demonstrated that combined pharmacotherapy and behavioral treatment produced superior long-term functional outcomes compared to medication alone [9].

What Done Prescribes

Done providers prescribe across the standard ADHD pharmacopeia:

First-line stimulants:

• Mixed amphetamine salts (Adderall, Adderall XR): typical starting dose 10 to 20 mg/day
• Lisdexamfetamine (Vyvanse): typical starting dose 30 mg/day
• Methylphenidate (Concerta, Ritalin): typical starting dose 18 to 36 mg/day extended-release

Non-stimulant alternatives:

• Atomoxetine (Strattera): 40 to 80 mg/day target dose
• Bupropion (Wellbutrin XL): 150 to 300 mg/day, used off-label for ADHD with comorbid depression
• Viloxazine (Qelbree): FDA-approved for adult ADHD in 2023 at 200 to 600 mg/day [10]

According to American Academy of Pediatrics and adult ADHD guidelines, stimulants remain first-line for uncomplicated adult ADHD, with response rates of 70 to 80% compared to 50 to 60% for non-stimulants [11]. Done's prescribing appears to follow this evidence hierarchy, though individual provider variability exists.

Schedule II prescriptions (all stimulants) require monthly video follow-up under current DEA regulations. Non-stimulants like atomoxetine can be prescribed with longer intervals between visits.

How Much Done Costs

Done's pricing as of early 2026:

• Initial evaluation: $199 (included in first month's subscription)
• Monthly membership: $199/month for standard tier; $299/month for "priority" tier with faster scheduling
• Medication cost: Not included. Patients fill prescriptions at retail pharmacies. Generic amphetamine salts cost approximately $30, $60/month with GoodRx coupons; brand-name Vyvanse runs $350, $400/month without insurance.

Annual costs depend on the subscription tier, medication selected, pharmacy pricing, and insurance reimbursement. Patients should compare Done's total out-of-pocket cost with available in-network psychiatric care and medication coverage.

Done's value proposition depends entirely on access. For the patient facing a 4-month wait for a psychiatrist, paying $199/month to start treatment within a week may be worth the premium. For someone with functioning insurance and available providers, the math does not favor Done.

Done vs. Alternatives

Several telehealth ADHD platforms compete directly with Done:

Cerebral ($85, $325/month): Offers therapy bundled with medication management. Better fit for patients wanting integrated behavioral support. Faced similar DOJ scrutiny in 2022.

ADHD Online ($199 one-time assessment, then per-visit): Uses a more comprehensive psychometric battery including the DIVA-5 structured diagnostic interview. Better fit for patients who want formal diagnostic certainty before starting medication.

Talkiatry (insurance-accepted): Full-scope telepsychiatry accepting major insurance plans. Wait times are longer (2 to 4 weeks) but costs are dramatically lower for insured patients.

Traditional psychiatry: May provide broader diagnostic assessment, therapy coordination, and continuity of care. Access to neuropsychological testing and other services varies by practice.

Done's appeal may include speed and simplicity for patients seeking medication management. No published survey has clearly characterized why patients choose Done or how often access concerns outweigh cost.

Clinical Risks and Limitations

Stimulant medications carry cardiovascular risks. The FDA requires black-box monitoring for sudden death in patients with structural cardiac abnormalities [14]. Done's intake asks about cardiac history, but the absence of physical examination means subclinical conditions (hypertrophic cardiomyopathy, undiagnosed arrhythmias) could be missed.

Cardiac screening before stimulant treatment generally includes medical and family history, blood pressure, and heart rate. A baseline EKG may be considered when cardiac symptoms or risk factors are present, but Done's implementation practices are unclear.

Diversion risk is another concern. Prescription stimulants can be shared, sold, or misused, so clinicians should assess risk and monitor treatment. Whether brief telehealth evaluations detect diversion less effectively than longitudinal in-person care has not been established.

Dr. David Goodman, director of the Adult Attention Deficit Disorder Center of Maryland and assistant professor at Johns Hopkins, stated in a 2023 interview with NPR: "The 30-minute telehealth visit cannot replicate the depth of a comprehensive ADHD evaluation. It can identify obvious cases, but subtle presentations and comorbid conditions require more time and clinical sophistication."

The Endocrine Society's guidelines on stimulant effects note that amphetamines can suppress appetite and reduce sleep quality, potentially affecting cortisol rhythms and metabolic health in long-term use [16]. Patients on Done should ensure their provider monitors weight, blood pressure, and sleep patterns at each monthly check-in.

What Done Reviews Actually Say

Trustpilot reviews of Done (as of early 2026) average 3.2/5 across approximately 2,800 reviews. Common positive themes include fast onboarding, responsive scheduling, and helpful individual providers. Common negative themes include difficulty canceling subscriptions, inconsistency between providers, and pharmacy coordination problems.

The Better Business Bureau shows a B+ rating with 147 complaints filed in the past 12 months, primarily regarding billing disputes and prescription delays.

"I was diagnosed within a week and started medication that changed my work performance," noted one representative positive review. "But when my provider left the platform, I had to re-do my entire intake with someone new who wanted to change my stable regimen." This experience highlights a structural weakness of platform-based care: provider turnover disrupts therapeutic continuity.

Who Should Look Elsewhere

Patients in these categories should not use Done as their primary ADHD provider:

• Adolescents under 18: Done does not treat minors. Pediatric ADHD requires different evaluation standards per AAP guidelines [17].
• Patients with active substance use disorders: Stimulant prescribing in this population requires addiction medicine expertise and close monitoring beyond monthly video visits.
• Patients needing formal neuropsychological testing: Done does not offer CPT, DIVA-5, or IQ-discrepancy analysis. These tools matter for disability accommodations, forensic evaluations, and complex differential diagnosis.
• Patients with bipolar disorder or psychotic features: Stimulants can trigger mania or psychosis. These patients need mood stabilization first, ideally under in-person psychiatric supervision.

The baseline heart rate and blood pressure measurement recommended before stimulant initiation requires either a home blood pressure cuff or a single in-person vital sign check. Done reportedly instructs patients to obtain home readings, though compliance verification is limited.